This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Atopy manifestations in pediatric patients with acute lymphoblastic leukemia: correlation assessment with interleukin-4 (IL-4) and IgE level
BMC Pediatrics Open Access 21 March 2022
-
MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways
British Journal of Cancer Open Access 12 September 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout


References
Barata JT, Keenan TD, Silva A, Boussiotis VA, Cardoso AA . Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica 2004; 89: 1459–1467.
de Sa Pinheiro A, Morrot A, Chakravarty S, Overstreet M, Bream JH, Irusta PM et al. IL-4 induces a wide-spectrum intracellular signaling cascade in CD8+ T cells. J Leukoc Biol 2007; 81: 1102–1110.
Stephenson LM, Park DS, Mora AL, Goenka S, Boothby M . Sequence motifs in IL-4R alpha mediating cell-cycle progression of primary lymphocytes. J Immunol 2005; 175: 5178–5185.
Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400–1406.
Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003; 100: 15113–15118.
Qiuping Z, Jei X, Youxin J, Wei J, Chun L, Jin W et al. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation. Cancer Res 2004; 64: 7579–7587.
Karawajew L, Ruppert V, Wuchter C, Kösser A, Schrappe M, Dörken B et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 upregulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood 2000; 96: 297–306.
Barata JT, Boussiotis VA, Yunes JA, Ferrando AA, Moreau LA, Veiga JP et al. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood 2004; 103: 1891–1900.
Acknowledgements
This study was supported by FCT PPCDT/SAU-OBS/58913 (JTB), SAU/13240 and CBO/34914 (AAC), and NIH RO1-CA104596 and RO1-AI43552 (VAB) grants. BAC and LRM have FCT-SFRH PhD and BI fellowships, respectively.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Cardoso, B., Martins, L., Santos, C. et al. Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia 23, 206–208 (2009). https://doi.org/10.1038/leu.2008.178
Published:
Issue date:
DOI: https://doi.org/10.1038/leu.2008.178
This article is cited by
-
Atopy manifestations in pediatric patients with acute lymphoblastic leukemia: correlation assessment with interleukin-4 (IL-4) and IgE level
BMC Pediatrics (2022)
-
MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways
British Journal of Cancer (2013)
-
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications
Leukemia (2012)
-
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
Leukemia (2011)
-
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
Leukemia (2010)